1. mRNA Chemistry & Directed Immune Activation
2. Antigen Identification
3. Lipid Chemistry & Delivery Formulation
More on TriMix & TetraMix
View our TriMix factsheet for my detailed information.
TriMix boosts immune response through the dendritic cell pathway in a sustainable way. eTheRNA’s TriMix contains three naked mRNA molecules:
1. caTLR4: Activates the immune system as it evokes dendritic cells to present antigens to the CD4/CD8 T-cells
2. CD40L: Induces the dendritic cells to initiate the antigen-specific action of the CD4 T-cells
3. CD70: Induces the dendritic cells to initiate the immune systems of the CD8 T-cells
TriMix is unique in the way it uses these three mRNA molecules to induce the proliferation of T-cells into either mature helper T-cells or cytotoxic T-cells – the ultimate ‘soldiers’ of the immune system that fight cancer cells and infectious agents. By combining TriMix with tumour-specific antigens or neoantigens the patient’s dendritic cells are stimulated to produce a more potent and larger population of antigen specific cytotoxic and helper T-cells compared to tumour antigens alone.
Initially, the TriMix technology was applied as an ex vivo product. The ex vivo product consists of dendritic cells extracted from the patient’s body, which are then, in the laboratory, modified with TriMix in combination with the tumour-specific antigen mRNA.
This cellular TriMix product is reinjected as an autologous product into the patient’s body.
In preclinical and phase I/IIa studies in advanced melanoma, the TriMix cellular ex vivo product – either as a standalone product or combined with a checkpoint inhibitor – was able to induce dendritic cells to elicit a powerful immune response, which in turn resulted in a promising clinical response and a prolonged disease-free survival rate.
eTheRNA is now turning this ex vivo approach into products that can be directly injected intranodally in the form of naked mRNA or intravenously and intramuscularly, where the mRNA is packaged in lipid nanoparticles.
Second generation of mRNA-based adjuvant boosting the immune response through the dendritic cell pathway. Building on the experience with TriMix, a new mix of immunostimulatory mRNAs was designed with further increased T-cell activating properties against the co-administered antigens.
© 2020 Etherna | Studio Hanswijk